- A new study found that REGEN-COV, a monoclonal antibody drug, can reduce the risk of coronavirus transmission by 81 percent.
- Experts say these findings are very encouraging and suggest that REGEN-COV is highly effective at preventing the symptomatic transmission of the coronavirus.
- They also say these findings mean healthcare professionals now have an option to speed antibody treatment against COVID-19.
One jab with Regeneron Pharmaceuticals’ monoclonal antibody drug reduced the infection risk of volunteers exposed to the coronavirus by 81 percent, the company announced April 12 in a press release.
This was a phase 3, double-blind, placebo-controlled trial. It was jointly run by the National Institute of Allergy and Infectious Diseases (NIAID).
Results showed that the drug (REGEN-COV), when administered beneath the skin by injection, reduced the risk of symptomatic infections by 81 percent in people who did not have an infection when the trial began.
Source: healthline